TY - JOUR
T1 - Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer
AU - Keikes, Lotte
AU - de Vos-Geelen, Judith
AU - de Groot, Jan Willem B.
AU - Punt, Cornelis J. A.
AU - Simkens, Lieke H. J.
AU - Trajkovic-Vidakovic, Marija
AU - Portielje, Johanneke E. A.
AU - Vos, Allert H.
AU - Beerepoot, Laurens V.
AU - Hunting, Cornelis B.
AU - Koopman, Miriam
AU - van Oijen, Martijn G. H.
N1 - Funding Information:
This work was supported by the Dutch Digestive Foundation .
Funding Information:
Martijn G.H. van Oijen has received unrestricted research funding from Amgen, Bayer, Lilly, Merck-Serono, Nordic and Roche.
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/7
Y1 - 2019/7
N2 - Objective: To examine implementation and patients' and providers' participation and satisfaction of a newly developed decision support tool (DST) for patients with metastatic colorectal cancer (mCRC) in palliative setting.Methods: Our DST consisted of a consultation sheet and web-based tailored information for mCRC treatment options. We conducted an implementation trajectory in 11 Dutch hospitals and evaluated implementation, participation and satisfaction rates.Results: Implementation rates fluctuated between 3 and 72 handed out (median:23) consultation sheets per hospital with patients' login rates between 36% and 83% (median:57%). The majority of patients (68%) had (intermediate)-high participation scores. The median time spent using the DST was 38 min (IQR:18-56) and was highest for questions concerning patients' perspective (5 min). Seventy-six% of patients were (very) satisfied. The provider DST rating was 7.8 (scale 1-10) and participation ranged between 25 and 100%. Remaining implementation thresholds included providers' treatment preferences, resistance against shared decision-making and (over)confidence in shared decision-making concepts already in use.Conclusion: We implemented a DST with sufficient patient and oncologist satisfaction and high patient participation, but participation differed considerably between hospitals suggesting unequal adoption of our tool.Practice implications: Requirements for structural implementation are to overcome remaining thresholds and increase awareness for additional decision support. (C) 2019 Elsevier B.V. All rights reserved.
AB - Objective: To examine implementation and patients' and providers' participation and satisfaction of a newly developed decision support tool (DST) for patients with metastatic colorectal cancer (mCRC) in palliative setting.Methods: Our DST consisted of a consultation sheet and web-based tailored information for mCRC treatment options. We conducted an implementation trajectory in 11 Dutch hospitals and evaluated implementation, participation and satisfaction rates.Results: Implementation rates fluctuated between 3 and 72 handed out (median:23) consultation sheets per hospital with patients' login rates between 36% and 83% (median:57%). The majority of patients (68%) had (intermediate)-high participation scores. The median time spent using the DST was 38 min (IQR:18-56) and was highest for questions concerning patients' perspective (5 min). Seventy-six% of patients were (very) satisfied. The provider DST rating was 7.8 (scale 1-10) and participation ranged between 25 and 100%. Remaining implementation thresholds included providers' treatment preferences, resistance against shared decision-making and (over)confidence in shared decision-making concepts already in use.Conclusion: We implemented a DST with sufficient patient and oncologist satisfaction and high patient participation, but participation differed considerably between hospitals suggesting unequal adoption of our tool.Practice implications: Requirements for structural implementation are to overcome remaining thresholds and increase awareness for additional decision support. (C) 2019 Elsevier B.V. All rights reserved.
KW - Metastatic colorectal cancer
KW - Decision support tool
KW - Shared decision-making
KW - Patient values
KW - Treatment preferences
KW - COMBINATION CHEMOTHERAPY
KW - OXALIPLATIN
KW - IRINOTECAN
KW - AIDS
U2 - 10.1016/j.pec.2019.02.020
DO - 10.1016/j.pec.2019.02.020
M3 - Article
SN - 0738-3991
VL - 102
SP - 1331
EP - 1335
JO - Patient Education and Counseling
JF - Patient Education and Counseling
IS - 7
ER -